Current Challenges in Chronic Bronchial Infection in Patients with Chronic Obstructive Pulmonary Disease

Currently, chronic obstructive pulmonary disease (COPD) patients and their physicians face a number of significant clinical challenges, one of which is the high degree of uncertainty related to chronic bronchial infection (CBI). By reviewing the current literature, several challenges can be identified, which should be considered as goals for research. One of these is to establish the bases for identifying the biological and clinical implications of the presence of potentially pathogenic microorganisms in the airways that should be more clearly elucidated according to the COPD phenotype. Another urgent area of research is the role of long-term preventive antibiotics. Clinical trials need to be carried out with inhaled antibiotic therapy to help clarify the profile of those antibiotics. The role of inhaled corticosteroids in patients with COPD and CBI needs to be studied to instruct the clinical management of these patients. Finally, it should be explored and confirmed whether a suitable antimicrobial treatment during exacerbations may contribute to breaking the vicious circle of CBI in COPD. The present review addresses the current state of the art in these areas to provide evidence which will enable us to progressively plan better healthcare for these patients.

[1]  D. Graziani,et al.  Clinical Management of COPD in a Real-World Setting. A Big Data Analysis , 2021 .

[2]  M. Martínez-García,et al.  Consensus Document on the Diagnosis and Treatment of Chronic Bronchial Infection in Chronic Obstructive Pulmonary Disease. , 2020, Archivos de bronconeumologia.

[3]  J. Curtis,et al.  Blood Eosinophil Counts in Clinical Trials for Chronic Obstructive Pulmonary Disease , 2020, American journal of respiratory and critical care medicine.

[4]  D. Graziani,et al.  Clinical Management of COPD in a Real-World Setting. A Big Data Analysis. , 2020 .

[5]  A. Agustí,et al.  BRONCHIAL INFECTION AND temporal evolution OF bronchiectasis in patients with chronic obstructive pulmonary disease. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  S. Johnston,et al.  LONG TERM IMPACT OF INHALED CORTICOSTEROID USE IN ASTHMA AND COPD: REVIEW OF MECHANISMS THAT UNDERLIE RISKS. , 2020, The Journal of allergy and clinical immunology.

[7]  A. Agustí,et al.  Inhaled Steroids, Circulating Eosinophils, Chronic Airway Infection and Pneumonia Risk in Chronic Obstructive Pulmonary Disease: A Network Analysis. , 2020, American journal of respiratory and critical care medicine.

[8]  H. Ochs-Balcom,et al.  Impact of Pseudomonas aeruginosa Isolation on Mortality and Outcomes in an Outpatient Chronic Obstructive Pulmonary Disease Cohort , 2020, Open forum infectious diseases.

[9]  M. Miravitlles,et al.  Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2019 Report: Future Challenges. , 2020, Archivos de Bronconeumologia.

[10]  R. Dessau,et al.  Pseudomonas aeruginosa and risk of death and exacerbations in patients with chronic obstructive pulmonary disease: an observational cohort study of 22.053 patients. , 2020, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[11]  D. Bouros,et al.  Low penetrance of antibiotics in the epithelial lining fluid. Experience from the use of inhaled antibiotics in patients with non CF-bronchiectasis. , 2019, Pulmonary pharmacology & therapeutics.

[12]  Yuejun Du,et al.  Inhaled corticosteroids and risk of pneumonia in patients with chronic obstructive pulmonary disease: A meta-analysis of randomized controlled trials. , 2019, International immunopharmacology.

[13]  G. Verleden,et al.  Azithromycin during Acute COPD Exacerbations Requiring Hospitalization (BACE): a Multicentre, Randomized, Double-blind, Placebo-controlled Trial. , 2019, American journal of respiratory and critical care medicine.

[14]  C. Montón,et al.  Nebulized Colistin And Continuous Cyclic Azithromycin In Severe COPD Patients With Chronic Bronchial Infection Due To Pseudomonas aeruginosa: A Retrospective Cohort Study , 2019, International journal of chronic obstructive pulmonary disease.

[15]  Thomas B. Clarke,et al.  Inhaled corticosteroid suppression of cathelicidin drives dysbiosis and bacterial infection in chronic obstructive pulmonary disease , 2019, Science Translational Medicine.

[16]  C. Daley,et al.  Comparative risks of chronic inhaled corticosteroids and macrolides for bronchiectasis , 2019, European Respiratory Journal.

[17]  X. Yao,et al.  Effects of long-term macrolide therapy at low doses in stable COPD , 2019, International journal of chronic obstructive pulmonary disease.

[18]  Meilan K. Han,et al.  Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019 , 2019, European Respiratory Journal.

[19]  G. Verleden,et al.  AZITHROMYCIN DURING ACUTE CHRONIC OBSTRUCTIVE PULMONARY DISEASE EXACERBATIONS REQUIRING , 2019 .

[20]  M. Tunney,et al.  British Thoracic Society Guideline for bronchiectasis in adults , 2018, Thorax.

[21]  M. Vitacca,et al.  Bacterial Colonization in COPD Patients Admitted to a Rehabilitation Respiratory Unit and Impact on Length of Stay: A Real-Life Study , 2018, COPD.

[22]  Yan Chen,et al.  Long-term macrolide treatment for the prevention of acute exacerbations in COPD: a systematic review and meta-analysis , 2018, International journal of chronic obstructive pulmonary disease.

[23]  H. Mukae,et al.  The microbiome in the lower respiratory tract. , 2018, Respiratory investigation.

[24]  A. Anzueto,et al.  Chronic Obstructive Pulmonary Disease Exacerbations: A Need for Action. , 2018, The American journal of medicine.

[25]  C. Strange,et al.  Inhaled corticosteroids for chronic obstructive pulmonary disease: what is their role in therapy? , 2018, International journal of chronic obstructive pulmonary disease.

[26]  M. Martínez-García,et al.  Current and future pharmacotherapy options for non-cystic fibrosis bronchiectasis , 2018, Expert review of respiratory medicine.

[27]  S. Johnston,et al.  Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations , 2018, Nature Communications.

[28]  C. Morin,et al.  The Efficacy of MAG-DHA for Correcting AA/DHA Imbalance of Cystic Fibrosis Patients , 2018, Marine drugs.

[29]  James R. Brown,et al.  Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations , 2018, Thorax.

[30]  C. Olveira,et al.  Spanish Guidelines on Treatment of Bronchiectasis in Adults. , 2017, Archivos de bronconeumologia.

[31]  James R. Brown,et al.  Sputum microbiome temporal variability and dysbiosis in chronic obstructive pulmonary disease exacerbations: an analysis of the COPDMAP study , 2017, Thorax.

[32]  C. Olveira,et al.  Spanish Guidelines on the Evaluation and Diagnosis of Bronchiectasis in Adults , 2017 .

[33]  R. Cantón,et al.  Normativa sobre el tratamiento de las bronquiectasias en el adulto , 2017 .

[34]  J. Raduà,et al.  Effectiveness of treatment with nebulized colistin in patients with COPD , 2017, International journal of chronic obstructive pulmonary disease.

[35]  A. Spanevello,et al.  Long-term effects of inhaled corticosteroids on sputum bacterial and viral loads in COPD , 2017, European Respiratory Journal.

[36]  T. Welte,et al.  European Respiratory Society guidelines for the management of adult bronchiectasis , 2017, European Respiratory Journal.

[37]  J. Kwong,et al.  The risk of mycobacterial infections associated with inhaled corticosteroid use , 2017, European Respiratory Journal.

[38]  J. Soriano,et al.  Spanish Guidelines for Management of Chronic Obstructive Pulmonary Disease (GesEPOC) 2017. Pharmacological Treatment of Stable Phase. , 2017, Archivos de bronconeumologia.

[39]  M. Miravitlles,et al.  Bronchiectasis in COPD patients: more than a comorbidity? , 2017, International journal of chronic obstructive pulmonary disease.

[40]  M. Davoli,et al.  Inhaled Corticosteroid Use in Chronic Obstructive Pulmonary Disease and Risk of Pneumonia: A Nested Case-Control Population-based Study in Lazio (Italy)—The OUTPUL Study , 2017, COPD.

[41]  Philip M. Hansbro,et al.  INVITED REVIEW SERIES: UNRAVELLING THE MANY FACES OF COPD TO OPTIMIZE ITS CARE AND OUTCOMES , 2017 .

[42]  Wouter A. A. de Steenhuijsen Piters,et al.  The microbiota of the respiratory tract: gatekeeper to respiratory health , 2017, Nature Reviews Microbiology.

[43]  John R. Hurst,et al.  Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline , 2017, European Respiratory Journal.

[44]  É. Rousseau,et al.  Novel n-3 PUFA monoacylglycerides of pharmacological and medicinal interest: Anti-inflammatory and anti-proliferative effects. , 2016, European journal of pharmacology.

[45]  O. Sibila,et al.  Pseudomonas aeruginosa resistance patterns and clinical outcomes in hospitalized exacerbations of COPD , 2016, Respirology.

[46]  M. Tunney,et al.  The role of anaerobic bacteria in the cystic fibrosis airway , 2016, Current opinion in pulmonary medicine.

[47]  Y. Kong,et al.  Effect of Fluoroquinolones and Macrolides on Eradication and Resistance of Haemophilus influenzae in Chronic Obstructive Pulmonary Disease , 2016, Antimicrobial Agents and Chemotherapy.

[48]  M. Miravitlles,et al.  Treatment of patients with COPD and recurrent exacerbations: the role of infection and inflammation , 2016, International journal of chronic obstructive pulmonary disease.

[49]  J. van der Palen,et al.  Safety and Tolerability of Nebulized Amoxicillin-Clavulanic Acid in Patients with COPD (STONAC 1 and STONAC 2) , 2016, COPD.

[50]  T. Welte,et al.  Report of the European Respiratory Society/European Cystic Fibrosis Society task force on the care of adults with cystic fibrosis , 2015, European Respiratory Journal.

[51]  É. Rousseau,et al.  Reversal of IL-13-induced inflammation and Ca(2+) sensitivity by resolvin and MAG-DHA in association with ASA in human bronchi. , 2015, Prostaglandins & other lipid mediators.

[52]  M. Greenstone,et al.  Prolonged antibiotics for non-cystic fibrosis bronchiectasis in children and adults. , 2015, The Cochrane database of systematic reviews.

[53]  J. Wedzicha,et al.  Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial , 2015, Thorax.

[54]  I. Pavord,et al.  Airway bacteria measured by quantitative polymerase chain reaction and culture in patients with stable COPD: relationship with neutrophilic airway inflammation, exacerbation frequency, and lung function , 2015, International journal of chronic obstructive pulmonary disease.

[55]  A. Anzueto,et al.  Antibiotic prophylaxis in COPD: Why, when, and for whom? , 2015, Pulmonary pharmacology & therapeutics.

[56]  Yahong Chen,et al.  Bacterial Infection, Airway and Systemic Inflammation and Clinical Outcomes before and after Treatment of AECOPD, a Longitudinal and Cross-sectional Study , 2015, COPD.

[57]  M. Polkey,et al.  Does a single Pseudomonas aeruginosa isolation predict COPD mortality? , 2014, European Respiratory Journal.

[58]  C. Montón,et al.  Pseudomonas aeruginosa isolates in severe chronic obstructive pulmonary disease: characterization and risk factors , 2014, BMC Pulmonary Medicine.

[59]  H. Hoogsteden,et al.  Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. , 2014, The Lancet. Respiratory medicine.

[60]  J. Wedzicha,et al.  Human rhinovirus infection during naturally occurring COPD exacerbations , 2014, European Respiratory Journal.

[61]  A. Anzueto,et al.  Antibiotics for treatment and prevention of exacerbations of chronic obstructive pulmonary disease. , 2013, The Journal of infection.

[62]  P. Poole,et al.  Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD). , 2013, The Cochrane database of systematic reviews.

[63]  Antonio Anzueto,et al.  Antibiotics for acute and chronic respiratory infection in patients with chronic obstructive pulmonary disease. , 2013, American journal of respiratory and critical care medicine.

[64]  S. Nambiar,et al.  Cardiovascular risks with azithromycin. , 2013, The New England journal of medicine.

[65]  E. Brass Cardiovascular risks with azithromycin. , 2013, The New England journal of medicine.

[66]  C. Olveira,et al.  Inhaled antibiotics for the treatment of chronic bronchopulmonary Pseudomonas aeruginosa infection in cystic fibrosis: systematic review of randomised controlled trials , 2013, Expert opinion on pharmacotherapy.

[67]  J. Alexander,et al.  Cardiovascular risks with azithromycin and other antibacterial drugs. , 2013, The New England journal of medicine.

[68]  G. Rogers,et al.  Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition , 2013, Thorax.

[69]  M. Miravitlles,et al.  Chronic bronchial infection in COPD. Is there an infective phenotype? , 2012, Respiratory Medicine.

[70]  J. Maurer Acute Exacerbations of Chronic Obstructive Pulmonary Disease: Identification of Biologic Clusters and Their Biomarkers , 2012 .

[71]  A. Anzueto,et al.  Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results , 2011, European Respiratory Journal.

[72]  M. Miravitlles,et al.  Sputum colour and bacteria in chronic bronchitis exacerbations: a pooled analysis , 2011, European Respiratory Journal.

[73]  M. Rodríguez-Carballeira,et al.  Pseudomonas aeruginosa and Mortality after Hospital Admission for Chronic Obstructive Pulmonary Disease , 2011, Respiration.

[74]  Christopher E Brightling,et al.  Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. , 2011, American journal of respiratory and critical care medicine.

[75]  C. Montón,et al.  International Journal of Copd Dovepress Long-term Azithromycin Therapy in Patients with Severe Copd and Repeated Exacerbations , 2022 .

[76]  John Connett,et al.  Azithromycin for prevention of exacerbations of COPD. , 2011, The New England journal of medicine.

[77]  S. Johnston,et al.  Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation. , 2011, American journal of respiratory and critical care medicine.

[78]  T. Seemungal,et al.  Reported pneumonia in patients with COPD: findings from the INSPIRE study. , 2011, Chest.

[79]  R. Cantón,et al.  Infección bronquial crónica: el problema de Pseudomonas aeruginosa , 2011 .

[80]  J. DiNicolantonio,et al.  Azithromycin for prevention of exacerbations of COPD. , 2011, The New England journal of medicine.

[81]  R. del Campo,et al.  [Chronic bronchial infection: the problem of Pseudomonas aeruginosa]. , 2011, Archivos de bronconeumologia.

[82]  W. MacNee,et al.  Effect of 6 Months of Erythromycin Treatment on Inflammatory Cells in Induced Sputum and Exacerbations in Chronic Obstructive Pulmonary Disease , 2010, Respiration.

[83]  R. Cosentini,et al.  Prophylactic antibiotic therapy in chronic obstructive pulmonary disease , 2010, Therapeutic advances in respiratory disease.

[84]  F. Blasi,et al.  Long-term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy. , 2010, Pulmonary pharmacology & therapeutics.

[85]  M. Miravitlles,et al.  Colour of sputum is a marker for bacterial colonisation in chronic obstructive pulmonary disease , 2010, Respiratory research.

[86]  J. Wedzicha,et al.  Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial , 2010, Respiratory research.

[87]  Pradeep K. Singh,et al.  Azithromycin maintains airway epithelial integrity during Pseudomonas aeruginosa infection. , 2010, American Journal of Respiratory Cell and Molecular Biology.

[88]  B. Tümmler,et al.  Pseudomonas aeruginosa population biology in chronic obstructive pulmonary disease. , 2009, The Journal of infectious diseases.

[89]  M. Sala,et al.  Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections , 2009, Infection.

[90]  M. Rodríguez-Carballeira,et al.  Pseudomonas aeruginosa in patients hospitalised for COPD exacerbation: a prospective study , 2009, European Respiratory Journal.

[91]  T. Murphy Pseudomonas aeruginosa in adults with chronic obstructive pulmonary disease , 2009, Current opinion in pulmonary medicine.

[92]  M. Salvadó,et al.  Mortality of COPD Patients Infected with Multi-Resistant Pseudomonas aeruginosa: A Case and Control Study , 2009, Infection.

[93]  M. Maciá,et al.  Chronic Pseudomonas aeruginosa infection in chronic obstructive pulmonary disease. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[94]  T. Seemungal,et al.  Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. , 2008, American journal of respiratory and critical care medicine.

[95]  R. Negro,et al.  Tobramycin Nebulizer Solution in severe COPD patients colonized with Pseudomonas aeruginosa: effects on bronchial Inflammation , 2008, Advances in therapy.

[96]  T. Murphy,et al.  Pseudomonas aeruginosa in chronic obstructive pulmonary disease. , 2008, American journal of respiratory and critical care medicine.

[97]  S. Johnston,et al.  Rhinovirus exposure impairs immune responses to bacterial products in human alveolar macrophages , 2008, Thorax.

[98]  M. Niederman,et al.  A Prediction Model for Bacterial Etiology in Acute Exacerbations of COPD , 2007, Infection.

[99]  S. Sethi,et al.  Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. , 2006, American journal of respiratory and critical care medicine.

[100]  A. Oliver,et al.  Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. , 2005, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[101]  A. Torres,et al.  Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease. , 2005, Archives of internal medicine.

[102]  H. Lode,et al.  Levofloxacin versus clarithromycin in COPD exacerbation: focus on exacerbation-free interval , 2004, European Respiratory Journal.

[103]  M. Pouladi,et al.  Impact of cigarette smoke on clearance and inflammation after Pseudomonas aeruginosa infection. , 2004, American journal of respiratory and critical care medicine.

[104]  B. Grant,et al.  Strain-specific immune response to Haemophilus influenzae in chronic obstructive pulmonary disease. , 2004, American journal of respiratory and critical care medicine.

[105]  P. Poole,et al.  Prophylactic antibiotic therapy for chronic bronchitis. , 2013, The Cochrane database of systematic reviews.

[106]  M. Miravitlles Exacerbations of chronic obstructive pulmonary disease: when are bacteria important? , 2002, European Respiratory Journal.

[107]  M. Yamaya,et al.  Erythromycin and common cold in COPD. , 2001, Chest.

[108]  T. Pelliniemi,et al.  Trimethoprim prophylaxis of acute exacerbations in chronic obstructive pulmonary diseases. , 2009, Acta medica Scandinavica.

[109]  D. Smith,et al.  Five-year winter chemoprophylaxis for chronic bronchitis , 1969, British medical journal.

[110]  P. Bergstein,et al.  Continuous suppressive antimicrobial treatment in chronic infected bronchitis during the winter months. , 1967, Diseases of the chest.

[111]  H. C. Couch Value of chemoprophylaxis and chemotherapy in early chronic bronchitis. A report to the Medical Research Council by their working party on trials of chemotherapy in early chronic bronchitis. , 1966, British medical journal.

[112]  P. Stradling,et al.  A trial of continuous winter chemotherapy in chronic bronchitis. , 1960, Lancet.

[113]  C. Spicer,et al.  Chemotherapy in Chronic Bronchitis , 1960 .

[114]  W. Leckie,et al.  Evaluation of Continuous Antibiotic Therapy in Chronic Bronchitis , 1959, British medical journal.

[115]  E. Moyes,et al.  Long-continued treatment with tetracycline and prednisolone in chronic bronchitis; a controlled trial. , 1957, Lancet.